"unresectable tumors" trang 2 - tải miễn phí từ tailieunhanh
Báo cáo khoa học:

Báo cáo khoa học: "Curative resection of a primarily unresectable acinar cell carcinoma of the pancreas after chemotherapy"
6    44    0
Báo cáo khoa học:

Báo cáo khoa học: "Transarterial chemoembolisation (TACE) using irinotecan-loaded beads for the treatment of unresectable metastases to the liver in patients with colorectal cancer: an interim report"
12    68    0
Báo cáo khoa học:

Báo cáo khoa học: "Large volume unresectable locally advanced nonsmall cell lung cancer: acute toxicity and initial outcome results with rapid arc"
9    97    0
Báo cáo khoa học:

Báo cáo khoa học: " Docetaxel- and 5-FU-concurrent radiotherapy in patients presenting unresectable locally advanced pancreatic cancer: a FNCLCC-ACCORD/0201 randomized phase II trial’s pre-planned analysis and case report of a 5.5-year disease-free survival"
7    53    0
Treatment outcomes of unresectable hepatocellular carcinoma by transarterial chemoembolisation combined with radiofrequency ablation

Treatment outcomes of unresectable hepatocellular carcinoma by transarterial chemoembolisation combined with radiofrequency ablation
5    100    0
Atezolizumab plus modified docetaxelcisplatin-5-fluorouracil (mDCF) regimen versus mDCF in patients with metastatic or unresectable locally advanced recurrent anal squamous cell carcinoma: A randomized, non-comparative phase II SCARCE GERCOR trial

Atezolizumab plus modified docetaxelcisplatin-5-fluorouracil (mDCF) regimen versus mDCF in patients with metastatic or unresectable locally advanced recurrent anal squamous cell carcinoma: A randomized, non-comparative phase II SCARCE GERCOR trial
11    89    0
Long-term survival trends in patients with unresectable stage III non-small cell lung cancer receiving chemotherapy and radiation therapy: A SEER cancer registry analysis

Long-term survival trends in patients with unresectable stage III non-small cell lung cancer receiving chemotherapy and radiation therapy: A SEER cancer registry analysis
6    94    0
Quality of life study of patients with unresectable locally advanced or metastatic pancreatic adenocarcinoma treated with gemcitabine+nab-paclitaxel versus gemcitabine alone: AX-PANC-SY001, a randomized phase-2 study

Quality of life study of patients with unresectable locally advanced or metastatic pancreatic adenocarcinoma treated with gemcitabine+nab-paclitaxel versus gemcitabine alone: AX-PANC-SY001, a randomized phase-2 study
7    60    0
First-line single-agent panitumumab in frail elderly patients with wild-type RAS unresectable colorectal cancer: A phase II study protocol OGSG 1602

First-line single-agent panitumumab in frail elderly patients with wild-type RAS unresectable colorectal cancer: A phase II study protocol OGSG 1602
5    54    0
Prognostic value of lymph node to primary tumor standardized uptake value ratio in unresectable esophageal cancer

Prognostic value of lymph node to primary tumor standardized uptake value ratio in unresectable esophageal cancer
9    66    0
The relationship between peripheral neuropathy and efficacy in second-line chemotherapy for unresectable advanced gastric cancer: A prospective observational multicenter study protocol (IVY)

The relationship between peripheral neuropathy and efficacy in second-line chemotherapy for unresectable advanced gastric cancer: A prospective observational multicenter study protocol (IVY)
6    83    0
Docetaxel, Cisplatin, and 5-fluorouracil (DCF) chemotherapy in the treatment of metastatic or unresectable locally recurrent anal squamous cell carcinoma: A phase II study of French interdisciplinary GERCOR and FFCD groups (Epitopes-HPV02 study)

Docetaxel, Cisplatin, and 5-fluorouracil (DCF) chemotherapy in the treatment of metastatic or unresectable locally recurrent anal squamous cell carcinoma: A phase II study of French interdisciplinary GERCOR and FFCD groups (Epitopes-HPV02 study)
8    34    1
Study protocol for an open-label, singlearm, phase Ib/II study of combination of toripalimab, nab-paclitaxel, and gemcitabine as the first-line treatment for patients with unresectable pancreatic ductal adenocarcinoma

Study protocol for an open-label, singlearm, phase Ib/II study of combination of toripalimab, nab-paclitaxel, and gemcitabine as the first-line treatment for patients with unresectable pancreatic ductal adenocarcinoma
8    54    1
AtezoTRIBE: A randomised phase II study of FOLFOXIRI plus bevacizumab alone or in combination with atezolizumab as initial therapy for patients with unresectable metastatic colorectal cancer

AtezoTRIBE: A randomised phase II study of FOLFOXIRI plus bevacizumab alone or in combination with atezolizumab as initial therapy for patients with unresectable metastatic colorectal cancer
9    87    1
A multicenter survey of first-line treatment patterns and gene aberration test status of patients with unresectable Stage IIIB/IV nonsquamous non-small cell lung cancer in China (CTONG 1506)

A multicenter survey of first-line treatment patterns and gene aberration test status of patients with unresectable Stage IIIB/IV nonsquamous non-small cell lung cancer in China (CTONG 1506)
7    65    1
TRIBE-2: A phase III, randomized, openlabel, strategy trial in unresectable metastatic colorectal cancer patients by the GONO group

TRIBE-2: A phase III, randomized, openlabel, strategy trial in unresectable metastatic colorectal cancer patients by the GONO group
8    32    1
The safety and efficacy of percutaneous intraductal radiofrequency ablation in unresectable malignant biliary obstruction: A single-institution experience

The safety and efficacy of percutaneous intraductal radiofrequency ablation in unresectable malignant biliary obstruction: A single-institution experience
8    51    1
Safety assessment of sorafenib in Chinese patients with unresectable hepatocellular carcinoma: Sanalysis of the GIDEON study

Safety assessment of sorafenib in Chinese patients with unresectable hepatocellular carcinoma: Sanalysis of the GIDEON study
11    65    1
Vemurafenib in Chinese patients with BRAFV600 mutation–positive unresectable or metastatic melanoma: An open-label, multicenter phase I study

Vemurafenib in Chinese patients with BRAFV600 mutation–positive unresectable or metastatic melanoma: An open-label, multicenter phase I study
7    60    1
A Phase I clinical trial of EUS-guided intratumoral injection of the oncolytic virus, HF10 for unresectable locally advanced pancreatic cancer

A Phase I clinical trial of EUS-guided intratumoral injection of the oncolytic virus, HF10 for unresectable locally advanced pancreatic cancer
9    27    1